Releases Geral
Colliers releases 2023 Global Sustainability Report
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 4 de junho de 2024
Colliers International Group Inc
TORONTO, June 04, 2024 (GLOBE NEWSWIRE) — Diversified professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) released its fourth annual Global Sustainability Report, summarizing progress on its commitment to create a more sustainable future.
Notable 2023 achievements include:
- 24.8% reduction in Scope 1 and 2 emissions per square foot from a 2021 baseline
- Validation of Scope 1, 2 and 3 emissions targets by the Science Based Targets initiative
- 33.5% women in management roles company-wide, up 1.8% since 2021
- Achieving a WELL Health-Safety rating in 35% of Colliers offices larger than 2,500 sq. ft., up from 10% in 2022
- Tripling the number of electric vehicles in fleet
- 5,819 days contributed towards volunteering efforts by Colliers professionals
In a year marked by economic and geopolitical uncertainty, we remain focused on the issues that will accelerate the success for both Colliers and our clients now and in the long term. In doing so, we are continuing to create value for all of our stakeholders, said Jay Hennick, Global Chairman & CEO of Colliers.
This report reflects the collective efforts of our teams worldwide, as well as our ongoing partnerships with tenants, suppliers, and local communities. Im proud of our momentum and the actions we are taking, which will have a significant positive impact on our enterprise and society, said Sean Drygas, Global Head of Sustainability at Colliers.
Colliers report was produced with reference to the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB, now consolidated into the International Sustainability Standards Board) and the Taskforce on Climate-related Financial Disclosures (TCFD) to ensure strong governance of its sustainability program. For more information, visit www.colliers.com/sustainability.
About Colliers
Colliers (NASDAQ, TSX: CIGI) is a leading diversified professional services and investment management company. With operations in 68 countries, our 19,000 enterprising professionals work collaboratively to provide expert real estate and investment advice to clients. For more than 29 years, our experienced leadership with significant inside ownership has delivered compound annual investment returns of approximately 20% for shareholders. With annual revenues of $4.3 billion and $96 billion of assets under management, Colliers maximizes the potential of property and real assets to accelerate the success of our clients, our investors and our people. Learn more at corporate.colliers.com, X @Colliers or LinkedIn.
Media contact:
Andrea Cheung
+1 416 324 6402
andrea.cheung@colliers.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c685ad2-23b1-40f5-a59a-2f011f65ab4c
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral 80 countries participate in Ministerial Roundtable
2 de janeiro de 2024Future Minerals Forum RIYADH, Saudi Arabia, Jan. 02, 2024 (GLOBE NEWSWIRE) — The Future Minerals Forum (FMF) announced today that its Ministerial Roundtable, due to be held on 9 January 2024,
Saiba Mais -
Releases Geral The Yacht Club de Monaco celebrates sporting and environmental achievements of 2023
22 de dezembro de 2023Yacht Club de Monaco MONACO, Dec. 22, 2023 (GLOBE NEWSWIRE) — (LaPresse) – To celebrate an eventful 2023 and the 70th anniversary of the Yacht Club de Monaco, Prince Albert II of Monaco,
Saiba Mais -
Releases Geral Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
8 de janeiro de 2024Essential Pharma Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa
Saiba Mais